BioMarin initiated with a Neutral at Guggenheim. Guggenheim analyst Whitney Ijem started BioMarin Pharmaceuticals with a Neutral rating. The analyst expects continued growth from the company’s existing commercial portfolio, though she thinks “near-term optionality is priced in at this point.” Ijem struggles to find an upside catalyst for shares in 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.